MétaCan
← tous les travaux

Efficacy of medical grade honey against multidrug-resistant organisms of operational significance

2014· article· en· 16 citations· W2091972792 sur OpenAlex· 10.1097/ta.0000000000000324

Pourquoi ce travail est-il dans la base ?

Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.

Porte sur le CanadaSon objet est le Canada, où que soient ses auteurs.

Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.

Le tri à trois modèles

les 1 000 travaux triés →

Les trois modèles l'ont jugé hors champ.

strate : about_only · poids de sondage : 3321.24 (l'échantillon est stratifié ; tout taux calculé sans le poids est faux)
Claude Opus 4.8OUT
genre : empirical
porte sur le Canada: non
confiance: high

In vitro efficacy of medical grade honey against multidrug-resistant organisms; 'validation' here is laboratory antimicrobial testing, and the object is wound treatment.

GPT-5.6 (high)OUT
genre : empirical
porte sur le Canada: non
confiance: high

The study tests medical honey against resistant organisms, not research itself.

Grok 4.5OUT
genre : empirical
porte sur le Canada: non
confiance: high

Clinical microbiology efficacy of medical-grade honey against pathogens; therapeutic domain.

Résumé

BACKGROUND: MEDIHONEY (Derma Sciences, Inc., Toronto, Ontario M1S 3S4, Canada) was cleared by the Food and Drug Administration for use on tramatic wounds, diabetic ulcers, and second-degree burns against normal skin flora but not necessarily against multidrug-resistant organisms (MDROs) infecting these wounds or its associated recovery and healing rate. METHODS: Here, we report on the efficacy of this medical grade honey treatment against two MDROs (Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus [MRSA]). In this initial phase (Part I), an in-laboratory validation and characterization of the efficacy against antibiotic-resistant bacteria were performed in vitro. RESULTS: The antimicrobial resistance of both MDROs was confirmed in vitro using standard microbiology techniques and species' DNA signatures. The minimum inhibitory concentration of the MEDIHONEY was determined to be 3.5% for MRSA and 8.5% for A. baumannii. The minimum bactericidal concentrations determined against MRSA and multidrug-resistant A. baumannii were shown to be 9.5% and 10.5%, respectively. CONCLUSION: Our in vitro findings support the efficacy of MEDIHONEY against MRSA and A. baumannii as requested by first responders. We also conducted screening assays using other "supermarket brands" of honey. All cultures from the latter showed bacterial and fungal growths. The use of supermarket brand honey for wound treatment is discouraged.

Conservé avec la notice de tri, où il sert de preuve aux étiquettes ci-dessus.

La notice

Revue
The Journal of Trauma: Injury, Infection, and Critical Care
Thématique
Bee Products Chemical Analysis
Domaine
Agricultural and Biological Sciences
Établissements canadiens
Organismes subventionnaires
Air Force Surgeon GeneralCongressionally Directed Medical Research ProgramsU.S. Air Force
Mots-clés
Acinetobacter baumanniiMicrobiologyStaphylococcus aureusMultiple drug resistanceAntimicrobialAntibioticsClearanceMedicineMinimum inhibitory concentrationMethicillin-resistant Staphylococcus aureusAcinetobacterDrug resistanceBiologyBacteriaPseudomonas aeruginosa
Résumé présent dans OpenAlex
oui